FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4379281036> ?p ?o ?g. }

• W4379281036 endingPage "e18663" @default.
• W4379281036 startingPage "e18663" @default.
• W4379281036 abstract "e18663 Background: Despite the high survival associated with Hodgkin lymphoma (HL), established disparities exist both in survival for Black and Hispanic patients and their access to consolidative treatments like radiotherapy as demonstrated using large, population-based databases. Elderly patients with HL face inferior survival compared to younger patients. Brentuximab is an approved second line therapy for those patients with refractory/relapsed HL. We examined whether there were inequities in receipt of treatment among those diagnosed with HL in a contemporary cohort receiving frontline doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), allowing for evaluation of targeted therapy. Methods: Data from Surveillance Epidemiology and End-Results (SEER) linked to Medicare claims were used to identify individuals diagnosed with HL from 2008 to 2017 who received frontline treatment with ABVD using applicable Healthcare Common Procedure Coding System codes. We examined differences in associations with receipt of brentuximab following ABVD within two years of diagnosis. Descriptive statistics were used to characterize the sample. We ran univariable and multivariable logistic regression models (producing adjusted odds ratios, aOR and 95% confidence intervals, CI) predicting treatment with brentuximab. Multivariable models were adjusted for age at diagnosis, sex, race/ethnicity, stage, insurance at diagnosis, and geographic location. Results: A total of 2,651 people diagnosed with HL were identified, 2,007 (76%) of which survived two years and 1,475 (56%) were still alive at last follow-up in 2019. Mean age at diagnosis was 69 years (SD: 12.4), most were men (N = 1,457, 55%), non-Hispanic White (N = 2,050, 77%), Hispanic (N = 291, 11%), or non-Hispanic Black (N = 220, 8%), diagnosed with stage I or II disease (N = 1,591, 60%), and received radiotherapy (N = 663, 23%) or brentuximab (N = 181, 7%) within two years of diagnosis. On univariable analysis, race and ethnicity did not have a statistically significant association with receipt of brentuximab as adjuvant treatment within two years of diagnosis. On multivariable analysis, individuals without insurance at diagnosis (aOR 1.54; 95% CI 1.02, 2.30) or those diagnosed with stage III or IV disease (aOR 2.04; 95% CI 1.04, 2.98) were more likely to receive brentuximab as adjuvant treatment within two years of diagnosis, after adjusting for the variables described above. Conclusions: Although we cannot definitively say that receipt of brentuximab within two years of diagnosis following ABVD is due to relapse, we posit that this can be used as a proxy for relapse. Our analysis did not demonstrate that race and ethnicity rose to traditional levels of statistical significance regarding associations with decreased odds of receiving brentuximab. In multivariable analysis, patients without insurance or diagnosed with stage III or IV disease were more likely to receive brentuximab." @default.
• W4379281036 created "2023-06-05" @default.
• W4379281036 creator A5001898266 @default.
• W4379281036 creator A5033401378 @default.
• W4379281036 creator A5033534353 @default.
• W4379281036 creator A5039679910 @default.
• W4379281036 creator A5052505769 @default.
• W4379281036 creator A5086463593 @default.
• W4379281036 date "2023-06-01" @default.
• W4379281036 modified "2023-09-27" @default.
• W4379281036 title "Evaluating access to brentuximab in elderly patients with Hodgkin lymphoma." @default.
• W4379281036 doi "https://doi.org/10.1200/jco.2023.41.16_suppl.e18663" @default.
• W4379281036 hasPublicationYear "2023" @default.
• W4379281036 type Work @default.
• W4379281036 citedByCount "0" @default.
• W4379281036 crossrefType "journal-article" @default.
• W4379281036 hasAuthorship W4379281036A5001898266 @default.
• W4379281036 hasAuthorship W4379281036A5033401378 @default.
• W4379281036 hasAuthorship W4379281036A5033534353 @default.
• W4379281036 hasAuthorship W4379281036A5039679910 @default.
• W4379281036 hasAuthorship W4379281036A5052505769 @default.
• W4379281036 hasAuthorship W4379281036A5086463593 @default.
• W4379281036 hasConcept C107130276 @default.
• W4379281036 hasConcept C126322002 @default.
• W4379281036 hasConcept C143998085 @default.
• W4379281036 hasConcept C156957248 @default.
• W4379281036 hasConcept C2776232574 @default.
• W4379281036 hasConcept C2776305933 @default.
• W4379281036 hasConcept C2776694085 @default.
• W4379281036 hasConcept C2776755627 @default.
• W4379281036 hasConcept C2778191690 @default.
• W4379281036 hasConcept C2779020855 @default.
• W4379281036 hasConcept C2779338263 @default.
• W4379281036 hasConcept C2779429289 @default.
• W4379281036 hasConcept C2780964509 @default.
• W4379281036 hasConcept C2908647359 @default.
• W4379281036 hasConcept C2992779791 @default.
• W4379281036 hasConcept C71924100 @default.
• W4379281036 hasConcept C72563966 @default.
• W4379281036 hasConcept C99454951 @default.
• W4379281036 hasConceptScore W4379281036C107130276 @default.
• W4379281036 hasConceptScore W4379281036C126322002 @default.
• W4379281036 hasConceptScore W4379281036C143998085 @default.
• W4379281036 hasConceptScore W4379281036C156957248 @default.
• W4379281036 hasConceptScore W4379281036C2776232574 @default.
• W4379281036 hasConceptScore W4379281036C2776305933 @default.
• W4379281036 hasConceptScore W4379281036C2776694085 @default.
• W4379281036 hasConceptScore W4379281036C2776755627 @default.
• W4379281036 hasConceptScore W4379281036C2778191690 @default.
• W4379281036 hasConceptScore W4379281036C2779020855 @default.
• W4379281036 hasConceptScore W4379281036C2779338263 @default.
• W4379281036 hasConceptScore W4379281036C2779429289 @default.
• W4379281036 hasConceptScore W4379281036C2780964509 @default.
• W4379281036 hasConceptScore W4379281036C2908647359 @default.
• W4379281036 hasConceptScore W4379281036C2992779791 @default.
• W4379281036 hasConceptScore W4379281036C71924100 @default.
• W4379281036 hasConceptScore W4379281036C72563966 @default.
• W4379281036 hasConceptScore W4379281036C99454951 @default.
• W4379281036 hasIssue "16_suppl" @default.
• W4379281036 hasLocation W43792810361 @default.
• W4379281036 hasOpenAccess W4379281036 @default.
• W4379281036 hasPrimaryLocation W43792810361 @default.
• W4379281036 hasRelatedWork W2068623214 @default.
• W4379281036 hasRelatedWork W2477071955 @default.
• W4379281036 hasRelatedWork W2499708454 @default.
• W4379281036 hasRelatedWork W2751234571 @default.
• W4379281036 hasRelatedWork W2891879965 @default.
• W4379281036 hasRelatedWork W2893570865 @default.
• W4379281036 hasRelatedWork W2991931587 @default.
• W4379281036 hasRelatedWork W3165566500 @default.
• W4379281036 hasRelatedWork W3199174616 @default.
• W4379281036 hasRelatedWork W4361946459 @default.
• W4379281036 hasVolume "41" @default.
• W4379281036 isParatext "false" @default.
• W4379281036 isRetracted "false" @default.
• W4379281036 workType "article" @default.